Clinical outcomes of progressive supranuclear palsy and multiple system atrophy

Brain

Volumn 131, Issue 5, 2008, Pages 1362-1372

  O'Sullivan, S S ^a,b   Massey, L A ^b   Williams, D R ^a,c   Silveira Moriyama, L ^a,b   Kempster, P A ^d   Holton, J L ^b   Revesz, T ^b   Lees, A J ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ALFRED HOSPITAL   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

Author keywords

Multiple system atrophy; Natural history; Progressive supranuclear palsy

Indexed keywords

LEVODOPA;

AGED; ARTICLE; AUTONOMIC DYSFUNCTION; BRAIN DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE DURATION; DISEASE SEVERITY; DYSPHAGIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE SUPRANUCLEAR PALSY; RESIDENTIAL CARE; RETROSPECTIVE STUDY; RICHARDSON DISEASE; SHY DRAGER SYNDROME; SPEECH DISORDER; SURVIVAL RATE; URINARY CATHETER; ADULT; DISEASE COURSE; HOSPITALIZATION; MIDDLE AGED; ONSET AGE; SEX DIFFERENCE; SURVIVAL; TIME;

ADULT; AGE OF ONSET; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SUPRANUCLEAR PALSY, PROGRESSIVE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 44949211482     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn065     Document Type: Article

References (42)

1. Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997; 48: 384-93.
2. Burn DJ, Warren NM. Toward future therapies in progressive supranuclear palsy. Mov Disord 2005; 20 (Suppl 12): S92-8.
3. Daniel SE, de Bruin VM, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 1995; 118 (Pt 3): 759-70.
4. DSM-IV. Diagnostic and statistical manual of mental disorders. Washington: American Psychiatric Association; 1995.
5. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain 1990; 113 (Pt 6): 1823-42.
6. Gibb GM, de Silva R, Revesz T, Lees AJ, Anderton BH, Hanger DP. Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy. Brain Res Mol Brain Res 2004; 121: 95-101.
7. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999; 163: 94-8.
8. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988; 38: 1031-4.
9. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007; 130: 1552-65.
10. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44: 2015-9.
11. Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992; 55: 1009-13.
12. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-70.
13. Hughes AJ, Daniel SE, Lees AJ. Idiopathic Parkinson's disease combined with multiple system atrophy. A clinicopathological report. Mov Disord 1991; 6: 342-6.
14. Katzenschlager R, Lees AJ. Treatment of Parkinson's disease: levodopa as the first choice. J Neurol 2002; 249 (Suppl 2): II19-24.
15. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: a clinicopathological study. Brain 2007 Aug;130(Pt 8):2123-8. Epub 2007 Jun 24.
16. Klockgether T, Ludtke R, Kramer B, Abele M, Burk K, Schols L, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 1998; 121 (Pt 4): 589-600.
17. Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996a; 55: 97-105.
18. Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996b; 60: 615-20.
19. Lowe JLG, Leigh PN. Greenfield's neuropathology. In: Graham DI, Lantos PL, editors. Disorders of movement and system degeneration. 6 edn., London: Arnold; 1997. p. 297-300.
20. Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1986; 36: 1005-8.
21. Maraganore DM, Anderson DW, Bower JH, McDonnell SK, Rocca WA. Autopsy patterns for Parkinson's disease and related disorders in Olmsted County, Minnesota. Neurology 1999; 53: 1342-4.
22. Morris HR, Gibb G, Katzenschlager R, Wood NW, Hanger DP, Strand C, et al. Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain 2002; 125: 969-75.
23. Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003; 60: 910-6.
24. Office of National Statistics. http://www.statistics.gov.uk/CCI/nugget. asp?ID=168&Pos=1&ColRank=1&Rank=374: Office for National Statistics, 2007. Accessed January 2008.
25. Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kilford L, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004; 127: 2657-71.
26. Papapetropoulos S, Gonzalez J, Mash DC. Natural history of progressive supranuclear palsy: a clinicopathologic study from a population of brain donors. Eur Neurol 2005; 54: 1-9.
27. Papapetropoulos S, Tuchman A, Laufer D, Papatsoris AG, Papapetropoulos N, Mash DC. Causes of death in multiple system atrophy. J Neurol Neurosurg Psychiatry 2007; 78: 327-9.
28. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989; 94: 79-100.
29. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354: 1771-5.
30. Schulz JB, Klockgether T, Petersen D, Jauch M, Muller-Schauenburg W, Spieker S, et al. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994; 57: 1047-56.
31. Tada M, Onodera O, Tada M, Ozawa T, Piao YS, Kakita A, et al. Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy. Arch Neurol 2007; 64: 256-60.
32. Testa D, Monza D, Ferrarini M, Soliveri P, Girotti F, Filippini G. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci 2001; 22: 247-51.
33. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002; 125: 1070-83.
34. Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 68: 434-40.
35. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995; 58: 160-6.
36. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994a; 117 (Pt 4): 835-45.
37. Wenning GK, Quinn N, Magalhaes M, Mathias C, Daniel SE. 'Minimal change' multiple system atrophy. Mov Disord 1994b; 9: 161-6.
38. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3: 93-103.
39. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997; 12: 133-47.
40. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005; 128: 1247-58.
41. Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007; 130: 1566-76.
42. Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry 2006; 77: 468-73.